Research programme: stem cell-based therapies - KadimastemAlternative Names: Astrocyte cell therapy - Kadimastem; AstroRX; Beta cell therapy - Kadimastem; Human pluripotent stem cell-based therapies - Kadimastem; Islet cell therapy - Kadimastem
Latest Information Update: 21 Mar 2017
At a glance
- Originator Kadimastem
- Class Stem cell therapies
- Mechanism of Action Cell replacements; Glial cell modulators; Neurogenesis stimulants; Pancreatic beta cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Type 1 diabetes mellitus